(2S)-3-aminooxypropane-1,2-diol | 737747-44-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2S)-3-aminooxypropane-1,2-diol
• CAS: 737747-44-3
• 化学式: C₃H₉NO₃
• 分子量: 107.109
• InChiKey: LHTDOTAGCRFCTB-VKHMYHEASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2
• 重原子数：
  7
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  75.7
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2S)-3-aminooxypropane-1,2-diol 、 在 三乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 N-[(2S)-2,3-dihydroxypropoxy]-5-(2-fluoro-4-iodoanilino)pyrimidine-4-carboxamide
  参考文献：
  名称：

  Structure-based design and synthesis of bicyclic fused-pyridines as MEK inhibitors

  摘要：

  The MAPK pathway is identified as one of the most important pathways involved in cell proliferation and differentiation. A key kinase in the pathway, the Mitogen-activated protein kinase kinase (MEK) is recognized as a promising target for antitumor drugs. Structure-based design and optimization of known MEK inhibitors resulted in identification of compound 10a as a potent non-ATP competitive MEK inhibitor in both in vitro and in vivo tests. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.03.086

文献信息

• Design and synthesis of orally available MEK inhibitors with potent in vivo antitumor efficacy
  作者：Mark E. Adams、Michael B. Wallace、Toufike Kanouni、Nicholas Scorah、Shawn M. O’Connell、Hiroshi Miyake、Lihong Shi、Petro Halkowycz、Lilly Zhang、Qing Dong

  DOI：10.1016/j.bmcl.2012.02.026

  日期：2012.4

  The structure-based design, synthesis, and biological evaluation of two novel series of potent and selective MEK kinase inhibitors are described herein. The elaboration of a lead pyrrole derivative to a bicyclic dihydroindolone core provided compounds with high potency and good drug-like pharmaceutical properties. Further scaffold modification afforded a series of dihydroindolizinone inhibitors, including an orally available advanced preclinical MEK inhibitor with potent in vivo antitumor efficacy. (C) 2012 Elsevier Ltd. All rights reserved.
• Structure-based design and synthesis of bicyclic fused-pyridines as MEK inhibitors
  作者：Hejun Lu、Wangyang Tu、Hongbo Fei、Guoji Xu、Qiyue Hu、Lei Zhang、Bing Lin、Jijun Yuan、Junzhao Yin、Aishen Gong、Mimi Wan、Dan Wang、Xiaoyan Zhu、Jun Feng、Qian Wang、Piaoyang Sun

  DOI：10.1016/j.bmcl.2014.03.086

  日期：2014.6

  The MAPK pathway is identified as one of the most important pathways involved in cell proliferation and differentiation. A key kinase in the pathway, the Mitogen-activated protein kinase kinase (MEK) is recognized as a promising target for antitumor drugs. Structure-based design and optimization of known MEK inhibitors resulted in identification of compound 10a as a potent non-ATP competitive MEK inhibitor in both in vitro and in vivo tests. (C) 2014 Elsevier Ltd. All rights reserved.